Home/Pipeline/R*ECL-AI-M Platform Therapeutics

R*ECL-AI-M Platform Therapeutics

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Empiriko

About Empiriko

Empiriko is a private, preclinical-stage biotech founded in 1993 and based in Cambridge, Massachusetts. The company is pioneering an integrated platform that combines a novel targeted drug delivery system (R*ECL-AI-M™) for radioligand and ADC therapies with a remote diagnostic monitoring device (PMF™). This dual-pronged approach aims to revolutionize personalized cancer treatment by enabling precise therapy delivery and at-home tracking of disease and drug response. Led by an experienced CEO and supported by a distinguished scientific advisory board, Empiriko is positioned at the convergence of targeted radiopharmaceuticals and digital health.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Disease

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active